Neoadjuvant Imatinib for an Uncommon Breast Malignancy Neoadjuvant Imatinib for an Uncommon Breast Malignancy
This case highlights the differentiation of dermatofibrosarcoma protuberans from metaplastic breast carcinoma and other spindle cell lesions, as well as the use of imatinib as neoadjuvant treatment.Journal of Medical Case Reports
Source: Medscape General Surgery Headlines - Category: Surgery Tags: Family Medicine/Primary Care Journal Article Source Type: news
More News: Breast Carcinoma | Cancer & Oncology | Carcinoma | Dermatology | Gleevec | Neoadjuvant Therapy | Primary Care | Surgery